MedTrace Logo

Surgical Versus Percutaneous Drainage in the Management of High Grade Pancreatic Trauma

NCT04335474 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2020-04-06

No results posted yet for this study

Summary

High-grade pancreatic injury is rare, and the reported complication and mortality are high.

The optimal management strategy according to high-grade injuries remains controversial.

The present study compares surgical drainage with percutaneous drainage in the management of High-grade pancreatic trauma.

Conditions

Interventions

PROCEDURE

Surgical drainage strategy

A laparotomy is performed and the operative approach to pancreatic trauma can consist of laparotomy with drainage of the peripancreatic area, distal pancreatectomy with or without preservation of the spleen, Rouxen-Y pancreaticojejunostomy, and, more seldom, pancreaticoduodenectomy. The type of operation depends on the grade of the pancreatic lesion. Spleen-preserving surgery will be attempted to avoid the lifelong increased risk of infections after splenectomy. In case of trauma where multiple organs are involved and an acute laparotomy is performed, the damage control surgery must be applied and the pancreatic resection will be done as part of a staged surgery.

PROCEDURE

Percutaneous drainage strategy

The nonoperative management consists of close monitoring of the patient's clinical condition; repeated radiological investigations such as CT, ultrasound, and MRCP; monitoring of the amylase and lipase levels, initiation of post-pyloric enteral nutrition and parenteral nutrition. In addition, ERCP with the placement of a stent in the damaged pancreatic duct is used as part of the non-operative approach. Besides, percutaneous catheter drainage (PCD) management including ultrasound or CT-guided drainage of abdominal and peripancreatic fluid collections and pancreatic pseudocysts is applied to the HGPT patient.

Sponsors & Collaborators

  • Nanjing PLA General Hospital

    lead OTHER

Principal Investigators

  • Weiwei Ding, MD · Medical School of Nanjing University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2022-12-31
Completion
2023-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04335474 on ClinicalTrials.gov